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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease that is characterized by memory loss and personality
changes. The age of onset in AD may vary widely and this is
the basis for the classification into early- and late-onset, with
60 or 65 yr being the usual cutoff point (1, 2). There are cur-
rently three known causative genes in early-onset AD (EOAD):
the amyloid precursor protein gene (APP) on chromosome 21
at 21q21.1 (3); the presenilin-1 gene (PSEN1) on chromo-
some 14 at 14q24.3 (4); and the presenilin-2 gene (PSEN2)
on chromosome 1 at 1q42.1 (5, 6). In addition, the apolipopro-
tein E (APOE) 4 allele has been reported to be a susceptibil-
ity gene for the development of familial and/or sporadic early-
and late-onset AD (7-9).
Mutations in the PSEN1 gene account for 18-55% of famil-
ial EOAD (1, 10). PSEN2 mutations are much rarer causes
of familial EOAD with 19 families being reported, includ-
ing the Volga-German kindred where a founder effect was
demonstrated (1, 2, 5, 6, 11). Twenty-seven different APP
mutations have been reported in 74 families and all mutations
are clustered in or adjacent to the amyloid  (A ) peptide
sequence, the major component of the amyloid plaques (12).
PSEN1 mutations, along with APP mutations, are believed
to be pathogenic by altering APP processing to change the
A 40:A 42 ratio (13, 14). 
In the Korean population, there has been only a single report
on a mutation in the PSEN1 gene in a pedigree of a 36-yr-old
familial AD (15). In this study, mutation analysis of the APP,
PSEN1, and PSEN2 genes was performed to determine the con-




Six patients were evaluated by a neurologist and were diag-
nosed of having AD according to the National Institute of
Neurological and Communicative Disorders and Stroke-Alz-
heimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) criteria (16). Computed tomography (CT), mag-
netic resonance image (MRI), and/or positron emission tomog-
raphy (PET) were performed to rule out other causes of demen-
tia. A family history was obtained from the patients or their
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Identification of PSEN1 and APP Gene Mutations in Korean Patients
with Early-Onset Alzheimer’ s Disease
Although mutations in three genes, amyloid precursor protein (APP), presenilin 1
(PSEN1), and presenilin 2 (PSEN2), have been identified as genetic causes of early-
onset Alzheimer s disease (EOAD), there has been a single report on a PSEN1
mutation in Koreans. In the present study, we performed a genetic analysis of six
Korean patients with EOAD. Direct sequencing analysis of the APP, PSEN1 and
PSEN2 genes revealed two different mutations of the PSEN1 gene (G206S and
M233T) and one mutation of the APP gene (V715M) in three patients with age-at-
onset of 34, 35, and 42 yr, respectively. In addition, two patients with age-at-onset
of 55 and 62 yr, respectively, were homozygous for APOE 4 allele. One woman
had no genetic alterations. These findings suggest that PSEN1 and APP gene
mutations may not be uncommon in Korean patients with EOAD and that genet-
ic analysis should be provided to EOAD patients not only for the identification of
their genetic causes but also for the appropriate genetic counseling.
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Genetic analysis
After obtaining informed consent, screening for mutations
in the APP, PSEN1, and PSEN2 genes were performed in the
patients with EOAD. All coding exons and their flanking
intronic sequences were analyzed for PSEN1 and PSEN2 genes
but selected exons (exons 16 and 17) were tested for APP.
Genomic DNA was extracted from peripheral blood leuko-
cytes using a Wizard Genomic DNA Purification Kit accord-
ing to the manufacturer’s instructions (Promega, Madison,
WI, U.S.A.). Each exon was amplified by polymerase chain
reaction (PCR) using the primers designed by the authors
(available on request). Direct sequencing was performed using
a BigDye Terminator Cycle Sequencing Ready Reaction kit
(Applied Biosystems, Foster City, CA, U.S.A.) on an ABI Prism
3100 genetic analyzer (Applied Biosystems). APOE genotyp-
ing was performed with a commercial kit using the multiplex




Table 1 gives a summary of clinical findings of the six patients
with EOAD. The mean age of onset was 43.6 yr (range, 34
to 62 yr), and all patients except patient 3 had a family history
of dementia (Fig. 1). All the patients showed progressive im-
pairment of their episodic memory. Patient 1 was diagnosed
as definite AD by a neuropathology study that showed neu-
ritic plaque, amyloid deposits and neurofibrillary tangles in
the brain. PET imaging of the glucose metabolism in all pa-
tients except patient 4 revealed severe hypometabolism in all
patients (Fig. 2). An EEG study was done in patients 1 and 2
and mild to moderate diffuse cerebral dysfunction was observed.
Molecular genetic findings
Two different mutations of the PSEN1 gene were detect-
ed (G206S and M233T) in patients 3 and 2 with an age of
onset of 34 and 35 yr, respectively. In the APP gene, one muta-
tion was detected (V715M) in patient 1 with the age of onset
of 41 yr. All were missense mutations and have been described
previously. PSEN2 gene analysis was performed in three pa-
tients without a mutation within either PSEN1 or APP, but
no mutation was detected. Two of them carried the APOE 4/
4 allele, and their age of onset was relatively late (62 and
55 yr) compared with the mutation positive patients and had
affected families with late-onset AD. Patient 6 did not have
any mutation. After identification of PSEN1 and APP muta-
tions in the patients, we tried to perform genetic analysis in
the family members of the patients but failed due to either
absence of living affected relatives or refusal of genetic analysis.
214 H.-K. Park, D.L. Na, J.-H. Lee, et al.
CT, computed tomography; K-MMSE, Korean Mini-Mental State Examination; MRI, magnetic resonance image; ND, not detected; PET, positron emis-
sion tomography.
Patient No. 1 2 3 4 5 6
Sex Male Female Female Male Female Female
Onset age (yr) 41 35 34 62 55 55
Family history + + - +++
Main clinical Memory and Memory and Memory and Memory Memory  Memory and
features visuospatial visuospatial visuospatial impairment, impairment, visuospatial
impairment, impairment,  impairment, irritability, anxiety, apraxia, irritability, impairment, 
apraxia, apraxia, apraxia, depression anxiety, apraxia,
bradykinesia, acalculia, aphasia, depression acalculia, anomia,
epilepsy aphasia optic ataxia aphasia
K-MMSE 10/30 (3 yr after 22/30 (3 yr after 20/30 (2 yr after 21/30 (3 yr after 18/30 (3 yr after 14/30 (2 yr after 
the first symptom) the first symptom) the first symptom) the first symptom) the first symptom) the first symptom)
4/30 (4 yr after 15/30 (5 yr after 11/30 (3 yr after
the first symptom) the first symptom) the first symptom)
Neuroimaging Progressive Bilateral Diffuse cerebral No ischemic Hypometabolism Severe
diffuse cortical frontotemporo- hypometabolism change in MRI in left frontal cortex, hypometabolism
atrophy in MRI parietal hypometa- in PET bilateral in bilateral parietal
and hypometa- bolism in PET and temporoparietal cortex, temporal
bolism in PET diffuse brain atrophy cortex in PET cortex and the
with ventriculomegaly left frontal cortex
in CT in PET
Mutation APP (V715M) PSEN1 (G206S) PSEN1 (M233T) ND ND ND
APOE genotype 3/ 3 3/ 3 3/ 4 4/ 4 4/ 4 3/ 3
Table 1. Clinical, radiological, and genetic findings of the Korean patients with early-onset Alzheimer’s diseaseDISCUSSION
In this study, we found two mutations in the PSEN1 gene,
G206S and M233T, and one mutation in the APP gene,
V715M, in three unrelated Korean patients. The V715M
mutation in the APP gene is the first mutation identified in
this gene in Korean patients with EOAD. This mutation was
previously detected in a French family and the age of onset of
the proband in the French family was 41 yr, which is same as
the onset age in our patient (10). In addition, the other fam-
ily members (two paternal uncles) developed dementia at ages
52 and 60, respectively. However, the family members of our
patient (the father and one paternal uncle) developed AD ear-
lier at ages 45 and around the 5th decade, respectively.
The G206S mutation in the PSEN1 gene has been report-
ed in two families (17, 18), and their age of onset was 30 to
35 yr, which is similar to that in our patients. The M233T
mutation was previously identified in French and Australian
families with 3-5 affected individuals in each family and the
mean age of onset of 35 yr (10, 17, 19). And, it is of note that
our patient showed rapidly progressive course by worsening
the Korean Mini-Mental State Examination (K-MMSE) score
from 20 at 2 yr after the first symptom into 4 at 2 yr later,
which might be due to the presence of the APOE  4 allele.
No mutations in the PSEN1, PSEN2, and APP genes were
found in 3 patients. Interestingly, the age of onset in these
patients was more than 20 yr later (55-62 yr old) than those
with identified mutations (34-42 yr old). They had a family
history of late-onset AD as well. Two of the three patients were
homozygous carriers for APOE 4 allele that could be clas-
sified into the AD type 2 (MIM 104310). In a Korean popu-
lation, it is reported that the frequency of APOE 4 allele is
0.09-0.128 (20-22) and that of genotype  4/ 4 was as low
as 0.006-0.009 (20, 21, 23).
Up to now, 27 mutations of the APP gene, 159 mutations
in the PSEN1 gene, and 11 mutations in the PSEN2 gene have
been reported in EOAD worldwide (www.molgen. ua.ac.be/
ADMutations). In previous reports, mutational analysis of
three genes in 96 autosomal dominant EOAD families led to
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Fig. 1. Pedigrees of Korean patients with EOAD. Numbers below
symbols are age-at-onset and age-at-deceased, respectively.
Circle, female; square, male; filled symbol, affected; open symbol,
not affected; open symbol with a question mark, affected status not




















Fig. 2. Comparison of brain FDG-PET images from a cognitively normal control and four patients with EOAD. FDG-PET images (B-E) show
variable degrees of hypometabolism in temporoparietal and frontal cortex, which are typical for Alzheimer’s disease. (A) a 55-yr-old healthy
Korean with a K-MMSE score of 30, (B) patient 2; 3 yr after the first symptom with a K-MMSE score of 22, (C) patient 3; 4 yr after the first
symptom with a K-MMSE score of 4, (D) patient 5; 3 yr after the first symptom with a K-MMSE score of 18; (E) patient 6; 3 yr after the first
symptom with a K-MMSE score of 11.
A B C D Ethe conclusion that 77% of cases in these families could be
attributed to mutations within the PSEN1 and APP genes
(10, 17, 24).
In Korea, there was only one report of genetically confirmed
case of EOAD (15). However, although the number of study
subjects was small, this study shows that PSEN1 or APP
gene mutations exist in other Korean patients with EOAD
and few reports on the EOAD patients confirmed by genet-
ic analysis might be due to under-utilization of genetic tests.
Therefore, we suggest that screening for PSEN1 and APP
gene mutations should be provided in Korean patients with
EOAD, especially in patients with age of onset <55, not only
for the molecular diagnosis of the patients but also for the
appropriate genetic counseling of the patients and their fam-
ily members. In addition, APOE genotype might be also
important to rule out familial AD in Koreans.
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